drugset / Trial / NCT03711188
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and efficacy of the combination of IMM-101 with nivolumab.
Timeline
- Start
- 2018-10-04
- Primary completion
- 2021-12-02
- Completion
- 2021-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM-101 | Other / unclassified | 0.1 ml | Other |
| Subject | IMM-101 | Other / unclassified | 10 mg/ml | Other |
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |